STAT+: ‘Here to stay’: How the pandemic helped build a burgeoning home testing industry

Healthcare Tech

Just a few years ago, the idea of at-home testing was practically antithetical to Caesar Djavaherian’s mission. The clinician and founder was laser-focused on serving people in person with his network of urgent care clinics. Fast forward to the spring of 2020, and his company — fresh off the heels of a merger with Carbon Health — was dashing to offer one of the first at-home test kits for Covid-19.

Home diagnostics have long been considered a kind of holy grail in telehealth: While a majority of virtual care can now be conducted remotely, the process of identifying a condition typically requires a physical visit. But a recent burst of activity in the sector — fueled by the pandemic and its need for rapid, remote tests — offers the potential to solve one of the industry’s thorniest last-mile problems.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Products You May Like

Articles You May Like

Healthcare workers say they need mental health services, but many aren’t getting them
U.S. states face steep decline in J&J Covid vaccine amid production problems at Baltimore plant
Opinion: A skeptic’s take on Neuralink and other consumer neurotech
Early Results from Federal Price Transparency Rule Show Difficultly in Estimating the Cost of Care
STAT+: Digital pharmacy startup Thirty Madison taps former Lilly exec as president